Skip to main content
BRTX
NASDAQ Industrial Applications And Services

BioRestorative Therapies Approves Over $727K in Executive Cash Bonuses Amid Going Concern Doubts

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.232
Mkt Cap
$5.943M
52W Low
$0.19
52W High
$2.045
52W Position info
22% above low
Off High info
89% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

BRTX sits 22% above its 52-week low of $0.19 on light trading volume (0.1× avg).

Summary

BioRestorative Therapies' Compensation Committee approved over $727,000 in cash bonuses for its executive officers for 2025, a significant payout for a company facing substantial doubt about its ability to continue as a going concern and a Nasdaq delisting notice.


Key Events · Executive and Board Changes · BRTX

  • Executive Cash Bonuses Approved

    The Compensation Committee approved cash bonuses totaling $727,500 for executive officers for the 2025 fiscal year.

  • CEO Compensation Details

    CEO Lance Alstodt was awarded a $300,000 cash bonus, contributing to a total compensation of over $2.4 million for 2025.

  • Financial Distress Context

    These significant bonuses are approved as the company faces substantial doubt about its ability to continue as a going concern and a Nasdaq delisting notice.


Analysis · BRTX · Industrial Applications And Services

This filing reveals substantial cash bonuses for executive officers, totaling $727,500, for the 2025 fiscal year. This amount represents over 12% of the company's current market capitalization. The approval of such significant bonuses raises serious concerns about capital allocation and corporate governance, especially given the company's previously disclosed 'going concern' issues and a Nasdaq delisting notice. While the company recently announced positive Phase 2 data, these executive payouts could negatively impact investor sentiment and further pressure the stock, as they suggest management is prioritizing executive compensation over the company's precarious financial health. Investors should scrutinize the company's cash burn and future financing needs in light of these compensation decisions.

How filings like this one have moved

In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BRTX was trading at $0.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9M. The 52-week trading range was $0.19 to $2.05. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRTX - Latest Insights

BRTX
Sep 11, 2026, 9:29 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.79
Real-time Price: $2.20 info
Change: -$0.590 (-21%) info
Market Cap: $2.956M info
BRTX
Sep 10, 2026, 4:30 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $2.71
Real-time Price: $2.20 info
Change: -$0.5068 (-19%) info
Market Cap: $2.956M info
BRTX
Sep 02, 2026, 5:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.160
Real-time Price: $2.20 info
Change: Reverse Stock Split info
Market Cap: $2.956M info
BRTX
Sep 01, 2026, 6:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1969
Real-time Price: $2.20 info
Change: Reverse Stock Split info
Market Cap: $2.956M info
BRTX
Aug 25, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.2225
Real-time Price: $2.20 info
Change: Reverse Stock Split info
Market Cap: $2.956M info